Skip to content
OpenCapital
Get started

Organon OGN Renflexis — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amgen logo
AMGNENBREL — Total revenues
$320M-37.3%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$555M+16.1%
AbbVie logo
ABBVRinvoq — Net revenues
$2.12B+23.3%
Amneal Pharmaceuticals, Inc. logo
AMRXBiosimilar — Net revenue
$22.3M-21.9%
Johnson & Johnson logo
JNJRemicade — Sales to customers (Note 9)
$422M-9.6%
AbbVie logo
ABBVSkyrizi — Net revenues
$4.48B+30.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's renflexis — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's renflexis — revenue?
Organon (OGN) reported renflexis — revenue of $57M in Q1 2026.
How has Organon's renflexis — revenue changed year-over-year?
Organon's renflexis — revenue decreased by 0.0% year-over-year, from $57M to $57M.
What is the long-term trend for Organon's renflexis — revenue?
Over 4 years (2021 to 2025), Organon's renflexis — revenue has grown at a 7.9% compound annual growth rate (CAGR), from $185M to $251M.
What does renflexis — revenue mean?
This metric represents the total net sales generated by the Renflexis biosimilar product line within the company's portfolio. It reflects the market demand and competitive positioning of this specific therapeutic asset in the global pharmaceutical landscape. Tracking these revenues helps investors evaluate the commercial performance and growth trajectory of the company's biosimilars segment.